AstraZeneca Pharma India Ltd. - Research Center
506820 ASTRAZEN Group (A) BSE data
Add to watchlist
| Results | |
| Statement |
Balance sheet
|
| More |
Balance sheet
(Rs crore)
| Mar ' 24 | Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | |
|---|---|---|---|---|---|
| Sources of funds | |||||
| Owner's fund | |||||
| Equity share capital | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Share application money | - | - | - | - | - |
| Preference share capital | - | - | - | - | - |
| Reserves & surplus | 706.92 | 583.69 | 506.39 | 451.17 | 359.44 |
| Loan funds | |||||
| Secured loans | - | - | - | - | - |
| Unsecured loans | - | - | - | - | - |
| Total | 711.92 | 588.69 | 511.39 | 456.17 | 364.44 |
| Uses of funds | |||||
| Fixed assets | |||||
| Gross block | 171.75 | 165.14 | 158.64 | 159.78 | 132.84 |
| Less : revaluation reserve | - | - | - | - | - |
| Less : accumulated depreciation | 105.07 | 96.28 | 84.15 | 78.82 | 61.31 |
| Net block | 66.68 | 68.86 | 74.49 | 80.96 | 71.53 |
| Capital work-in-progress | 0.27 | 1.33 | 2.20 | 4.02 | 24.24 |
| Investments | - | - | - | - | - |
| Net current assets | |||||
| Current assets, loans & advances | 1,011.08 | 914.68 | 779.87 | 689.73 | 610.59 |
| Less : current liabilities & provisions | 366.11 | 396.18 | 345.17 | 318.54 | 341.92 |
| Total net current assets | 644.97 | 518.50 | 434.70 | 371.19 | 268.67 |
| Miscellaneous expenses not written | - | - | - | - | - |
| Total | 711.92 | 588.69 | 511.39 | 456.17 | 364.44 |
| Notes: | |||||
| Book value of unquoted investments | - | - | - | - | - |
| Market value of quoted investments | - | - | - | - | - |
| Contingent liabilities | 138.25 | 132.28 | 124.60 | 89.17 | 69.19 |
| Number of equity sharesoutstanding (Lacs) | 250.00 | 250.00 | 250.00 | 250.00 | 250.00 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis